pone.0085549.pdf (1.88 MB)

Flk1+ and VE-Cadherin+ Endothelial Cells Derived from iPSCs Recapitulates Vascular Development during Differentiation and Display Similar Angiogenic Potential as ESC-Derived Cells

Download (1.88 MB)
journal contribution
posted on 13.08.2015, 00:00 by Erin E. Kohler, Kishore K. Wary, Fei Li, Ishita Chatterjee, Norifumi Urao, Peter T. Toth, Masuko Ushio-Fukai, Jalees Rehman, Changwon Park, Asrar B. Malik
RATIONALE: Induced pluripotent stem (iPS) cells have emerged as a source of potentially unlimited supply of autologous endothelial cells (ECs) for vascularization. However, the regenerative function of these cells relative to adult ECs and ECs derived from embryonic stem (ES) cells is unknown. The objective was to define the differentiation characteristics and vascularization potential of Fetal liver kinase (Flk)1(+) and Vascular Endothelial (VE)-cadherin(+) ECs derived identically from mouse (m)ES and miPS cells. METHODS AND RESULTS: Naive mES and miPS cells cultured in type IV collagen (IV Col) in defined media for 5 days induced the formation of adherent cell populations, which demonstrated similar expression of Flk1 and VE-cadherin and the emergence of EC progenies. FACS purification resulted in 100% Flk1(+) VE-cadherin(+) cells from both mES and miPS cells. Emergence of Flk1(+)VE-cadherin(+) cells entailed expression of the vascular developmental transcription factor Er71, which bound identically to Flk1, VE-cadherin, and CD31 promoters in both populations. Immunostaining with anti-VE-cadherin and anti-CD31 antibodies and microscopy demonstrated the endothelial nature of these cells. Each cell population (unlike mature ECs) organized into well-developed vascular structures in vitro and incorporated into CD31(+) neovessels in matrigel plugs implanted in nude mice in vivo. CONCLUSION: Thus, iPS cell-derived Flk1(+)VE-cadherin(+) cells expressing the Er71 are as angiogenic as mES cell-derived cells and incorporate into CD31(+) neovessels. Their vessel forming capacity highlights the potential of autologous iPS cells-derived EC progeny for therapeutic angiogenesis.




This work was supported by grants from the National Institutes of Health to KKW (HL079356), MUF (HL112293), JR (GM094220), and ABM (HL090152), and awards from the American Heart Association to EEK (12PRE1208000) and KKW (12GRNT12070159). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.



PLoS One





Issue date